Who is sponsoring NCT07159204?

NCT07159204 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT07159204?

Interventions in NCT07159204: Paclitaxel polymer micelle immunocombination.

What condition does NCT07159204 study?

NCT07159204 studies Biliary Tract Cancer (BTC).

Is NCT07159204 still recruiting?

NCT07159204 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT07159204: PILOT-BTC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

Recruiting now Phase 2 Last updated 8 September 2025

What this trial tests

Phase 2 trial testing Paclitaxel polymer micelle immunocombination in Biliary Tract Cancer (BTC) in 100 participants. Currently enrolling.

Timeline

1 January 2023

Primary endpoint
31 December 2025

1 July 2026

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 January 2023
Primary completion	31 December 2025
Estimated completion	1 July 2026
Sites	1 location across China

Drugs / interventions tested

Paclitaxel polymer micelle immunocombination — full drug profile →

Conditions studied

Biliary Tract Cancer (BTC) — all drugs for Biliary Tract Cancer (BTC) →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 75, any sex, with Biliary Tract Cancer (BTC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Biliary Tract Cancer (BTC)

Currently open trials in the same condition.

NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07197554 — A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies · Phase 1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07159204 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07159204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing